A multicenter, randomized, comparative trial on the effect of febuxostat in preventing cerebral and cardiorenovascular events in patients with hyperuricemia
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2019
Price : $35 *
At a glance
- Drugs Febuxostat (Primary) ; Allopurinol
- Indications Cardiovascular disorders; Cerebrovascular disorders; Hyperuricaemia; Kidney disorders
- Focus Therapeutic Use
- Acronyms FREED
- 07 Mar 2019 Primary endpoint of development of cerebral or cardiovascular events and all deaths has been met, according to results published in the European Heart Journal.
- 07 Mar 2019 Results published in the European Heart Journal
- 21 Nov 2018 Status changed from active, no longer recruiting to completed.